Local delivery of minocycline and systemic BCNU have synergistic activity in the treatment of intracranial glioma: J.L. Frazier, et al.; J. Neurooncol. 64, 203 (2003) Abstract
Minocycline exerts multiple inhibitory effects on vascular endothelial growth factor-induced smooth muscle cell migration: the role of ERK1/2, PI3K, and matrix metalloproteinases: J.S. Yao, et al.; Circ. Res. 95, 364 (2004) Abstract
Minocycline up-regulates Bcl-2 and protects against cell death in mitochondria: J. Wang, et al.; J. Biol. Chem. 279, 19948 (2004) Abstract
Minocycline up-regulates BCL-2 levels in mitochondria and attenuates male germ cell apoptosis: M. Castanares, et al.; BBRC 337, 663 (2005) Abstract
Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy: J.K. Krady, et al.; Diabetes 54, 1559 (2005) Abstract
Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations: C.C. Alano, et al.; PNAS 103, 9685 (2006) Abstract
Multiple neuroprotective mechanisms of minocycline in autoimmune CNS inflammation: K. Maier, et al.; Neurobiol. Dis. 25, 514 (2007) Abstract
Comparison of doxycycline and minocycline in the inhibition of VEGF-induced smooth muscle cell migration: J.S. Yao, et al.; Neurochem. Int. 50, 524 (2007) Abstract
Minocycline, a second-generation tetracycline, as a neuroprotective agent in an animal model of schizophrenia: Y. Levkovitz, et al.; Brain Res. 1154, 154 (2007) Abstract
|
